Novo Nordisk's hemophilia drug shows potential as once-monthly treatment

New phase I and II data supports the firm’s continued work toward a phase III of Mim8, a hemophilia drug that could achieve blockbuster status, according to some estimates.
by MarketWire, translated by Daniel Pedersen

Novo Nordisk’s hemophilia drug, Mim8, has ”demonstrated potential as a once-monthly treatment” for hemophilia A, the company reported in a Monday press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading